J-DOIT3 trial finds no clear HbA1c lower threshold for mortality in type 2 diabetes

Analysis of the long running randomised controlled trial was published 23 October 2026 in PLoS One.

Stands on 1 first-party reading of PubMed and ClinicalTrials.gov, not reporting.

An analysis of the J-DOIT3 randomised controlled trial has found no clear lower threshold of glycated hemoglobin associated with the lowest risk of all-cause mortality or myocardial infarction in people with type 2 diabetes. The study was published in PLoS One and listed on PubMed on 23 October 2026.^[1] The trial followed 1271 participants over 8.5 years. Authors reported no HbA1c threshold for minimum mortality was identified across the observed range. The analysis did find maintaining LDL cholesterol below 80 mg/dL was associated with reduced stroke risk.

Proof1 source · 1 publisher · signed

What this stands on

"Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial." published in PloS one as a randomized controlled trial (PubMed 42912779, doi 10.1371/journal.pone.0360295). Sample: 1271 as stated in the abstract. Duration: 8.5 years. Results as the authors report them: For glycemic control, our results revealed no clear lower threshold of · PubMed and ClinicalTrials.gov, read by the New studies instrument · the fact recordUnited Statesofficial source

Read directly from PubMed and ClinicalTrials.gov, the public registries of published studies and registered trials, not from anyone's report of it.